Trevi Therapeutics doubles authorized shares to 400M, adds 8M shares to equity plan

Filed June 4, 2026 · Period ending June 3, 2026 · ~1 min read

Key Changes

• high

  Shareholders approved doubling authorized common stock from 200 million to 400 million shares, effective June 3, 2026. This significantly expands the company's capacity for future capital raises, acquisitions, or employee compensation, which could dilute existing shareholders.

  Item 5.03 verify on EDGAR →
• medium

  Amended equity plan adds 8 million shares for employee and director stock awards, caps director compensation, and tightens share recycling rules to prevent reuse of shares used for tax withholding or option exercise.

  Item 5.07 verify on EDGAR →
• low

  Michael Heffernan elected as Class I director with term expiring at 2029 annual meeting. Ernst & Young ratified as independent auditor for fiscal year 2026.

  Item 5.07 verify on EDGAR →